Vermont is poised to become the first state requiring drug companies to explain their price increases, and Bob and Deborah Messing think that's a good idea.
The Messings live in Montpelier and are in their early 70s. She's on Orencia, a Bristol-Myers Squibb product, for rheumatoid arthritis. He recently finished a course of Harvoni, made by Gilead Sciences Inc., to treat hepatitis C.
The Vermont bill calls on state health care regulators to develop an annual list of up to 15 drugs that have seen the biggest price increases. Their manufacturers would then have to justify the increases to the attorney general's office.
No comments:
Post a Comment